166 related articles for article (PubMed ID: 25449436)
1. Low-dose cisplatin converts the tumor microenvironment into a permissive state for HSVtk-induced antitumor immunity in HPV16-related tonsillar carcinoma.
Goh AR; Shin SP; Jung NR; Ryu CH; Eom HS; Lee JH; Choi K; Lee SJ; Jung YS
Cancer Lett; 2015 Jan; 356(2 Pt B):743-50. PubMed ID: 25449436
[TBL] [Abstract][Full Text] [Related]
2. Adenovirus expressing both thymidine kinase and soluble PD1 enhances antitumor immunity by strengthening CD8 T-cell response.
Shin SP; Seo HH; Shin JH; Park HB; Lim DP; Eom HS; Bae YS; Kim IH; Choi K; Lee SJ
Mol Ther; 2013 Mar; 21(3):688-95. PubMed ID: 23337984
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic immunization and local low-dose tumor irradiation, a reinforcing combination.
Draghiciu O; Walczak M; Hoogeboom BN; Franken KL; Melief KJ; Nijman HW; Daemen T
Int J Cancer; 2014 Feb; 134(4):859-72. PubMed ID: 23922012
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity.
Chen ML; Yan BS; Lu WC; Chen MH; Yu SL; Yang PC; Cheng AL
Int J Cancer; 2014 Jan; 134(2):319-31. PubMed ID: 23818246
[TBL] [Abstract][Full Text] [Related]
5. Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer.
Spanos WC; Nowicki P; Lee DW; Hoover A; Hostager B; Gupta A; Anderson ME; Lee JH
Arch Otolaryngol Head Neck Surg; 2009 Nov; 135(11):1137-46. PubMed ID: 19917928
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic synergy of human papillomavirus E7 subunit vaccines plus cisplatin in an animal tumor model: causal involvement of increased sensitivity of cisplatin-treated tumors to CTL-mediated killing in therapeutic synergy.
Bae SH; Park YJ; Park JB; Choi YS; Kim MS; Sin JI
Clin Cancer Res; 2007 Jan; 13(1):341-9. PubMed ID: 17200373
[TBL] [Abstract][Full Text] [Related]
7. E10A, an adenovirus-carrying endostatin gene, dramatically increased the tumor drug concentration of metronomic chemotherapy with low-dose cisplatin in a xenograft mouse model for head and neck squamous-cell carcinoma.
Adhim Z; Lin X; Huang W; Morishita N; Nakamura T; Yasui H; Otsuki N; Shigemura K; Fujisawa M; Nibu K; Shirakawa T
Cancer Gene Ther; 2012 Feb; 19(2):144-52. PubMed ID: 22116375
[TBL] [Abstract][Full Text] [Related]
8. Decreased HPV-specific T cell responses and accumulation of immunosuppressive influences in oropharyngeal cancer patients following radical therapy.
Al-Taei S; Banner R; Powell N; Evans M; Palaniappan N; Tabi Z; Man S
Cancer Immunol Immunother; 2013 Dec; 62(12):1821-30. PubMed ID: 24146146
[TBL] [Abstract][Full Text] [Related]
9. Potent tumor-specific immunity induced by an in vivo heat shock protein-suicide gene-based tumor vaccine.
Ren W; Strube R; Zhang X; Chen SY; Huang XF
Cancer Res; 2004 Sep; 64(18):6645-51. PubMed ID: 15374979
[TBL] [Abstract][Full Text] [Related]
10. Adenovirus E1a protein enhances the cytotoxic effects of the herpes thymidine kinase-ganciclovir system.
Parada C; Hernández Losa J; Guinea J; Sánchez-Arévalo V; Fernández Soria V; Alvarez-Vallina L; Sánchez-Prieto R; Ramón y Cajal S
Cancer Gene Ther; 2003 Feb; 10(2):152-60. PubMed ID: 12536204
[TBL] [Abstract][Full Text] [Related]
11. Vaccine-induced tumor necrosis factor-producing T cells synergize with cisplatin to promote tumor cell death.
van der Sluis TC; van Duikeren S; Huppelschoten S; Jordanova ES; Beyranvand Nejad E; Sloots A; Boon L; Smit VT; Welters MJ; Ossendorp F; van de Water B; Arens R; van der Burg SH; Melief CJ
Clin Cancer Res; 2015 Feb; 21(4):781-94. PubMed ID: 25501579
[TBL] [Abstract][Full Text] [Related]
12. Induction of potent antitumor natural killer cell activity by herpes simplex virus-thymidine kinase and ganciclovir therapy in an orthotopic mouse model of prostate cancer.
Hall SJ; Sanford MA; Atkinson G; Chen SH
Cancer Res; 1998 Aug; 58(15):3221-5. PubMed ID: 9699645
[TBL] [Abstract][Full Text] [Related]
13. Interleukin 2 gene transfer prevents NKG2D suppression and enhances antitumor efficacy in combination with cisplatin for head and neck squamous cell cancer.
Li D; Ronson B; Guo M; Liu S; Bishop JS; Van Echo DA; O'Malley BW
Cancer Res; 2002 Jul; 62(14):4023-8. PubMed ID: 12124336
[TBL] [Abstract][Full Text] [Related]
14. Herpes simplex virus thymidine kinase/ganciclovir-mediated killing of tumor cell induces tumor-specific cytotoxic T cells in mice.
Yamamoto S; Suzuki S; Hoshino A; Akimoto M; Shimada T
Cancer Gene Ther; 1997; 4(2):91-6. PubMed ID: 9080117
[TBL] [Abstract][Full Text] [Related]
15. Antitumor effects of telomelysin in combination with paclitaxel or cisplatin on head and neck squamous cell carcinoma.
Kondo N; Tsukuda M; Kimura M; Fujita K; Sakakibara A; Takahashi H; Ishiguro Y; Toth G; Matsuda H
Oncol Rep; 2010 Feb; 23(2):355-63. PubMed ID: 20043095
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor immunity is involved in the thymidine kinase-mediated killing of tumors induced by activated Ki-ras(G12V).
Pavlovic J; Nawrath M; Tu R; Heinicke T; Moelling K
Gene Ther; 1996 Jul; 3(7):635-43. PubMed ID: 8818652
[TBL] [Abstract][Full Text] [Related]
17. Improved clearance during treatment of HPV-positive head and neck cancer through mTOR inhibition.
Coppock JD; Wieking BG; Molinolo AA; Gutkind JS; Miskimins WK; Lee JH
Neoplasia; 2013 Jun; 15(6):620-30. PubMed ID: 23730210
[TBL] [Abstract][Full Text] [Related]
18. Expression of costimulatory molecules: B7 and ICAM up-regulation after treatment with a suicide gene.
Ramesh R; Munshi A; Abboud CN; Marrogi AJ; Freeman SM
Cancer Gene Ther; 1996; 3(6):373-84. PubMed ID: 8988840
[TBL] [Abstract][Full Text] [Related]
19. HSV-1 Infection Modulates the Radioresponse of a HPV16-positive Head and Neck Cancer Cell Line.
Turunen A; Hukkanen V; Kulmala J; Syrjanen S
Anticancer Res; 2016 Feb; 36(2):565-74. PubMed ID: 26851010
[TBL] [Abstract][Full Text] [Related]
20. Delivery of herpes simplex thymidine kinase bystander effect by engineered human mesothelial cells for the treatment of ovarian cancer.
Rancourt C; Bergeron C; Lane D; Garon G; Piché A
Cytotherapy; 2003; 5(6):509-22. PubMed ID: 14660047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]